EUVIMEDEUVIMED entdecken
VergleichsstudieMultizentrische StudieRandomisierte kontrollierte Studie

Trigger point injections for myofascial pain in terminal cancer: a randomized trial

Hideaki Hasuo iD, Hiroto Ishiki, Yoshinobu Matsuda iD, Hiromichi Matsuoka iD, Kazuhiro Kosugi, Mei Xing, Yasushi Akiyama, Yoshihisa Matsumoto iD, Hideki Ishikawa

Pain Medicine · 01.01.2025 · 26 (1) · 14-21

DOI: 10.1093/pm/pnae084 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Pain Medicine, online erschienen am 10.10.2024. Verfasst von Hideaki Hasuo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychosomatic Medicine, Kansai Medical University, Osaka, Hirakata, Osaka, 573-1010, Japan. Hauptthemen laut MEDLINE: Anesthetics, Local, Lidocaine, Myofascial Pain Syndromes, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Grant for Research Advancement on Palliative Medicine, Japanese Society for Palliative Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The aim of this study was to evaluate the efficacy and safety of a single trigger point injection (TPI) of a local anesthetic for the treatment of myofascial pain syndrome (MPS) in patients with incurable cancer.

Methods

This multicenter, exploratory, open-label, randomized comparative trial was conducted in five specialized palliative care departments. Hospitalized patients with incurable cancer who had been experiencing pain related to MPS were randomized to receive either a TPI of 1% lidocaine plus conventional care (TPI group) or conventional care alone (control group). The short-term efficacy and occurrence of adverse events (AEs) were compared between groups. The primary endpoint was the percentage of patients who experienced a reduction in pain scores of ≥50%, assessed using an 11-point Numerical Rating Scale, at 3 days post-intervention. Adverse events were assessed using the Common Terminology Criteria for AEs v5.0.

Results

Fifty patients were enrolled, and the trial completion rate was 100%. The proportion of patients who experienced an improvement in Numerical Rating Scale pain scores of ≥50% was 70.8% (95% confidence interval, 52.4%-89.2%) in the TPI group and 0.0% in the control group; the difference was statistically significant (P < .001). In the TPI group, one case (4.2%) of Grade 1 nausea and 1 case (4.2%) of Grade 1 somnolence were reported.

Conclusion

A single TPI of a local anesthetic is safe and efficacious in inducing an immediate reduction in MPS-related pain in patients with incurable cancer. Clinical trials registration number: This study was registered with the Japan Registry of Clinical Trials (approval number: jRCTs051210132) on December 16, 2021. https://jrct.niph.go.jp/en-latest-detail/jRCTs051210132. Approval of the research protocol by a Certified Review Board: The present study was approved by the Wakayama Medical University (reference number: CRB5180004. Registered 26 May 2021).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anesthetics, LocalLidocaineMyofascial Pain SyndromesNeoplasmsTrigger PointsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCancer PainInjectionsPain MeasurementTreatment Outcome

Stichwörter der Autor:innen

incurable cancerlocal anesthesiamyofascial pain syndromepressure pain thresholdtrigger point injection

Substanzen

Anesthetics, LocalLidocaine

Autor:innen und Institutionen

  • Department of Psychosomatic Medicine, Kansai Medical University, Osaka, Hirakata, Osaka, 573-1010, Japan.
  • Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Department of Psychosomatic Internal Medicine, NHO Kinki-Chuo Chest Medical Center, Sakai, 591-8555, Japan.
  • Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, 277-8577, Japan.
  • Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 135-0063, Japan.

ORCID-Profile: Hideaki Hasuo, Yoshinobu Matsuda, Hiromichi Matsuoka, Yoshihisa Matsumoto

Förderung

  • Grant for Research Advancement on Palliative Medicine
  • Japanese Society for Palliative Medicine

Zitieren

APA

Hasuo, H., Ishiki, H., Matsuda, Y., Matsuoka, H., Kosugi, K., Xing, M., Akiyama, Y., Matsumoto, Y., & Ishikawa, H. (2025). Trigger point injections for myofascial pain in terminal cancer: a randomized trial. Pain Medicine, 26(1), 14-21. https://doi.org/10.1093/pm/pnae084

Vancouver

Hasuo H, Ishiki H, Matsuda Y, Matsuoka H, Kosugi K, Xing M, et al. Trigger point injections for myofascial pain in terminal cancer: a randomized trial. Pain Medicine. 2025;26(1):14-21. doi:10.1093/pm/pnae084

BibTeX
@article{Hasuo2025,
  author = {Hasuo, Hideaki and Ishiki, Hiroto and Matsuda, Yoshinobu and Matsuoka, Hiromichi and Kosugi, Kazuhiro and Xing, Mei and Akiyama, Yasushi and Matsumoto, Yoshihisa and Ishikawa, Hideki},
  title = {Trigger point injections for myofascial pain in terminal cancer: a randomized trial},
  journal = {Pain Medicine},
  year = {2025},
  volume = {26},
  number = {1},
  pages = {14--21},
  doi = {10.1093/pm/pnae084}
}
Kostenlos starten →